This was an excellent video for those of us who are metastatic. I learned a lot. The time stamps were very helpful for reviewing parts of the interview again. Thank you.
This is an amazingly thorough update of the varieties of treatment coming on line for prostate cancer. Great questions and so many insights from Dr. Lenzo. Great video!!
Timestamps: 0:45 Who is Nat Lenzo? 2:20 Targeted therapy success? 3:30 What are these companies/treatments? 5:39 Where are these new Theranostic centers? 6:03 Can patients contact Icon Group? 7:45 Can you define Theranostics and Nuclear Oncology? 9:40 How do you get a therapeutic agent to bind to the imaging agent? 11:37 What about Pluvicto? 12:12 Safety and tolerability? 14:02 What about Actinium? 15:50 Does Lutetium really work for one-third of patients? 19:30 Is Actinium a more potent isotope? Are there more side effects? 22:00 What test do you use for Lutetium and Actinium treatment? 23:30 What is eGFR? 25:55 Is BRCA testing recommended? 26:36 When is a Theranostic treatment most optimal? 30:00 What does positive BRCA testing mean? 31:05 Actinium vs. Lutetium results? 33:34 Actinium vs. Lutetium side effects? 35:05 What kind of PSA decline do you see with Actinium? 37:07 Where does Lead fit into all this? 40:09 How does the flux directly affect the patient? 41:43 Is there a direct way for patients to find trials? clinical trials.gov and a theranostics website? 42:35 What is Standard Uptake Value (SUV) and how significant is it to prostate cancer? 45:45 What are antibodies and how can they fight cancer? 49:21 What do antibody side effects look like? 50:42 Can antibodies work with other treatments? 51:37 Treatments for PSMA negative patients? 54:48 Are there any current trials with these multiple therapies? 55:37 Prostate Global coming to the United States using radio antibody 55:58 Alex's closing remarks
This was an incredibly helpful video! Watching from the UK but it’s great to have some information for our first consultation. Might not have everything available but worth asking about it.
🎯 Key points for quick navigation: 00:00 *🎥 Introduction to Nuclear Oncology* - Discussion on Lu-177, actinium, and new prostate cancer treatments, - Interview with Dr. Nat Lenzo, a nuclear oncologist involved in key studies. 02:08 *💡 Dr. Lenzo's Journey in Nuclear Oncology* - Dr. Nat Lenzo’s path from internal medicine to nuclear medicine, - His involvement with visionary experts in nuclear oncology and theragnostics. 03:32 *🌏 Overview of Dr. Lenzo's Companies* - Founding of Theranostics Australia and collaboration with Genesis Care, - Transition to Icon for its global footprint in oncology and theragnostics. 06:24 *🏥 Patient Access to Treatments* - Explanation of how patients can access Dr. Lenzo's treatments, - Details on his patient consultations and involvement in research. 07:19 *🔬 Key Definitions: Nuclear Oncology and Theragnostics* - Definition and differentiation of nuclear medicine oncology and theragnostics, - Explanation of theranostic pairs using imaging and therapeutic isotopes. 11:35 *🧬 Effectiveness and Safety of Lu-177 and Actinium* - Discussion on response variability in patients receiving Lu-177, - Safety, side effects, and efficacy analysis from various trials. 17:08 *🔄 Future of Theranostics* - Exploration of therapy enhancements and genomic considerations, - Combination treatments and potent alternatives like actinium. 21:59 *🩺 Blood and Kidney Function Concerns* - Differences between radiation and chemotherapy effects, - Platelet count is crucial due to prolonged declines, - Kidney function impacts treatment dosing and safety. 24:37 *🧬 Genomic Testing and Personalized Treatment* - Emphasis on genomic testing like BRCA for therapy selection, - Research on genomic markers for treatment responses, - Importance of genomic data in personalizing prostate cancer treatments. 26:45 *⚛️ Timing and Effectiveness of Radiation Therapies* - Earlier treatment may offer better outcomes but raises long-term concerns, - Potential DNA damage in earlier applications of radiation therapies, - Quality of life considerations in therapy timing and efficacy. 30:10 *🔬 Research and Real-World Data on Novel Agents* - Limited data available for actinium treatments, - Real-world evidence suggests better outcomes with early use, - Concerns about cumulative side effects and patient monitoring. 33:05 *🚀 Advancements in Radiopharmaceuticals* - Exploration of diverse isotopes and targeted therapies, - Developments in combining isotopes for enhanced treatment efficacy, - Continued research to mitigate side effects and improve quality of life. 43:15 *📊 Understanding SUV in PSMA Expression and Therapy* - SUV (Standard Uptake Value) assesses receptor intensity; higher SUV indicates better survival outcomes. - Therapeutic intent varies; quality of life may matter more than survival. - Antibody therapies may offer benefits even with lower SUV levels. 46:00 *🧬 Antibody Therapies in Nuclear Medicine* - Antibodies bind specifically to target receptors, offering better radiation delivery. - Long half-life in circulation allows for better treatment of hidden cancer cells. - More profound myotoxicity but potentially cost-effective due to lower doses. 51:00 *🌐 Emerging Therapies for PSMA Negative Cancers* - New agents targeting different receptors offer hope for PSMA-negative patients. - Combination therapies might enhance treatment effectiveness for various targets. - Clinical trials are essential for validating these emergent therapies. 54:00 *🔬 Personalized and Combination Cancer Therapies* - Future therapies will be tailored based on individual genetics, cancer type, and treatment history. - Combination treatments are more effective, integrating various therapeutic modes. - Telix’s global trial for radio antibodies highlights ongoing research efforts. 56:00 *🌍 Clinician Guidance and Clinical Trial Participation* - Clinical trials offer access to breakthrough therapies not yet FDA-approved. - Patients should be informed about their PSA metrics and treatment history. - Support resources like helplines can enhance patient knowledge and advocacy. Made with HARPA AI
Always a treat to hear of the amazing journey we are on as prostate cancer patients..and thanks to the Institute
This was an excellent video for those of us who are metastatic. I learned a lot. The time stamps were very helpful for reviewing parts of the interview again. Thank you.
This is an amazingly thorough update of the varieties of treatment coming on line for prostate cancer. Great questions and so many insights from Dr. Lenzo. Great video!!
Timestamps:
0:45 Who is Nat Lenzo?
2:20 Targeted therapy success?
3:30 What are these companies/treatments?
5:39 Where are these new Theranostic centers?
6:03 Can patients contact Icon Group?
7:45 Can you define Theranostics and Nuclear Oncology?
9:40 How do you get a therapeutic agent to bind to the imaging agent?
11:37 What about Pluvicto?
12:12 Safety and tolerability?
14:02 What about Actinium?
15:50 Does Lutetium really work for one-third of patients?
19:30 Is Actinium a more potent isotope? Are there more side effects?
22:00 What test do you use for Lutetium and Actinium treatment?
23:30 What is eGFR?
25:55 Is BRCA testing recommended?
26:36 When is a Theranostic treatment most optimal?
30:00 What does positive BRCA testing mean?
31:05 Actinium vs. Lutetium results?
33:34 Actinium vs. Lutetium side effects?
35:05 What kind of PSA decline do you see with Actinium?
37:07 Where does Lead fit into all this?
40:09 How does the flux directly affect the patient?
41:43 Is there a direct way for patients to find trials? clinical trials.gov and a theranostics website?
42:35 What is Standard Uptake Value (SUV) and how significant is it to prostate cancer?
45:45 What are antibodies and how can they fight cancer?
49:21 What do antibody side effects look like?
50:42 Can antibodies work with other treatments?
51:37 Treatments for PSMA negative patients?
54:48 Are there any current trials with these multiple therapies?
55:37 Prostate Global coming to the United States using radio antibody
55:58 Alex's closing remarks
This was an incredibly helpful video! Watching from the UK but it’s great to have some information for our first consultation. Might not have everything available but worth asking about it.
Another great interview I am on my 4th session of Pluvicto and the Dr is quite satisfied. I really appreciate these videos thank you very much!
What side effects are you experiencing?
I had my first dose of Pluvecto on August 26th and I didn’t experience any side effects… bring on the 2nd dose
How are you feeling now. Hubby had first dose
Your doctor is always satisfied, I suppose. How are you doing? That is the question.
Time stamps were incredibly useful. Thanks!
Excited about New Treatments 🙏🇺🇸 Hope they come soon 🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸
Great information from this channel, thanks.
Excellent discussion. Many thanks.
First :)
Nice content as always .
🎯 Key points for quick navigation:
00:00 *🎥 Introduction to Nuclear Oncology*
- Discussion on Lu-177, actinium, and new prostate cancer treatments,
- Interview with Dr. Nat Lenzo, a nuclear oncologist involved in key studies.
02:08 *💡 Dr. Lenzo's Journey in Nuclear Oncology*
- Dr. Nat Lenzo’s path from internal medicine to nuclear medicine,
- His involvement with visionary experts in nuclear oncology and theragnostics.
03:32 *🌏 Overview of Dr. Lenzo's Companies*
- Founding of Theranostics Australia and collaboration with Genesis Care,
- Transition to Icon for its global footprint in oncology and theragnostics.
06:24 *🏥 Patient Access to Treatments*
- Explanation of how patients can access Dr. Lenzo's treatments,
- Details on his patient consultations and involvement in research.
07:19 *🔬 Key Definitions: Nuclear Oncology and Theragnostics*
- Definition and differentiation of nuclear medicine oncology and theragnostics,
- Explanation of theranostic pairs using imaging and therapeutic isotopes.
11:35 *🧬 Effectiveness and Safety of Lu-177 and Actinium*
- Discussion on response variability in patients receiving Lu-177,
- Safety, side effects, and efficacy analysis from various trials.
17:08 *🔄 Future of Theranostics*
- Exploration of therapy enhancements and genomic considerations,
- Combination treatments and potent alternatives like actinium.
21:59 *🩺 Blood and Kidney Function Concerns*
- Differences between radiation and chemotherapy effects,
- Platelet count is crucial due to prolonged declines,
- Kidney function impacts treatment dosing and safety.
24:37 *🧬 Genomic Testing and Personalized Treatment*
- Emphasis on genomic testing like BRCA for therapy selection,
- Research on genomic markers for treatment responses,
- Importance of genomic data in personalizing prostate cancer treatments.
26:45 *⚛️ Timing and Effectiveness of Radiation Therapies*
- Earlier treatment may offer better outcomes but raises long-term concerns,
- Potential DNA damage in earlier applications of radiation therapies,
- Quality of life considerations in therapy timing and efficacy.
30:10 *🔬 Research and Real-World Data on Novel Agents*
- Limited data available for actinium treatments,
- Real-world evidence suggests better outcomes with early use,
- Concerns about cumulative side effects and patient monitoring.
33:05 *🚀 Advancements in Radiopharmaceuticals*
- Exploration of diverse isotopes and targeted therapies,
- Developments in combining isotopes for enhanced treatment efficacy,
- Continued research to mitigate side effects and improve quality of life.
43:15 *📊 Understanding SUV in PSMA Expression and Therapy*
- SUV (Standard Uptake Value) assesses receptor intensity; higher SUV indicates better survival outcomes.
- Therapeutic intent varies; quality of life may matter more than survival.
- Antibody therapies may offer benefits even with lower SUV levels.
46:00 *🧬 Antibody Therapies in Nuclear Medicine*
- Antibodies bind specifically to target receptors, offering better radiation delivery.
- Long half-life in circulation allows for better treatment of hidden cancer cells.
- More profound myotoxicity but potentially cost-effective due to lower doses.
51:00 *🌐 Emerging Therapies for PSMA Negative Cancers*
- New agents targeting different receptors offer hope for PSMA-negative patients.
- Combination therapies might enhance treatment effectiveness for various targets.
- Clinical trials are essential for validating these emergent therapies.
54:00 *🔬 Personalized and Combination Cancer Therapies*
- Future therapies will be tailored based on individual genetics, cancer type, and treatment history.
- Combination treatments are more effective, integrating various therapeutic modes.
- Telix’s global trial for radio antibodies highlights ongoing research efforts.
56:00 *🌍 Clinician Guidance and Clinical Trial Participation*
- Clinical trials offer access to breakthrough therapies not yet FDA-approved.
- Patients should be informed about their PSA metrics and treatment history.
- Support resources like helplines can enhance patient knowledge and advocacy.
Made with HARPA AI
super helpful video - what are some of the approved PCa antibody agents available in the US at the current time?
When any of these therapies come to market they will cost BIG bucks for sure!
8659 Batz Pike
Humans need 10 years.... AI will do it in 10 hours
Assuming data is good. Over 95% of studies are fraudulent! Closer to 99% for epidemiology studies.
I make pulvito
Actinium is basically a last resort nuke.
Sorry, Greek to me. Way above me head.
He is in Australia, how does this help in the US???
Research yields data. Data is used to gain regulatory approval. You DO NOT have to do trials in the US to get FDA approvals